FDA Declares Tirzepatide Shortage Resolved, Narrowing Path for Compounders
Friday, June 12th, 2026 — The U.S. Food and Drug Administration has determined that the nationwide shortage of tirzepatide injection, a dual GIP/GLP-1 drug sold by Eli Lilly under the brand names Mounjaro and Zepbound, has been resolved, the agency said in a CDER update. The shortage, first declared in 2022 amid surging demand for incretin-based weight-loss and diabetes treatments, had been the legal basis under which compounding pharmacies produced copies of tirzepatide.
The designation's removal has immediate regulatory consequences for thousands of pharmacies that compounded tirzepatide during the shortage period.
Regulators Lead the Story
Under federal law, pharmacies operating under Section 503A — typically traditional community pharmacies compounding to fill individual prescriptions — and outsourcing facilities operating under Section 503B are permitted to compound copies of approved drugs only when those drugs appear on the FDA's drug-shortage list. With tirzepatide no longer listed, compounders are expected to halt production unless they can demonstrate a clinically significant medical need that cannot be met by the commercial product.
The FDA maintains a running record of compounding actions, inspections, and recalls on its compounding oversight page. The agency has in recent years issued warning letters to compounders found marketing GLP-1 and GLP-1/GIP copies outside of shortage exemptions or in ways that raise safety concerns. Industry observers noted the regulator's language in recent statements has grown more specific about what constitutes a lawful shortage exception.
Compounding Pharmacies Face a Narrower Path
The outsourced-compounding industry, represented by groups including the Alliance for Pharmacy Compounding and the Outsourcing Facilities Association, has argued that shortages of specific dose strengths or formulations sometimes persist even after a broad shortage designation is lifted. The trade groups have previously lobbied for a more granular shortage framework that would allow continued compounding of individual SKUs still in constrained supply.
It is not yet clear whether Eli Lilly has resolved supply constraints at all dose levels. Shortage data is tracked on the FDA Drug Shortages database. Medriva's /tracker/ monitors ongoing compounding and regulatory developments in the GLP-1 space.
The National Association of Boards of Pharmacy and the HHS Office of Inspector General have separately signaled interest in pharmacy-compounding oversight, though neither has issued a tirzepatide-specific action as of Friday.
Pipeline Records Keep Retatrutide in Focus
While tirzepatide's regulatory status shifts, clinical-trial records show continued enrollment in studies of next-generation peptide drugs, including Eli Lilly's triple-agonist retatrutide and Novo Nordisk's combination therapy cagrisema. Trial listings on ClinicalTrials.gov indicate Phase 2 and Phase 3 programs are ongoing across obesity, type 2 diabetes, and metabolic liver disease.
Early-stage scientific literature indexed on PubMed and in journals including Nature continues to explore mechanisms of action and long-term safety signals for these agents. Medriva's dedicated /retatrutide/ page tracks trial milestones and published findings as they emerge.
Sports Anti-Doping Rules Remain Separate
Athletes subject to anti-doping testing should be aware that peptide hormones, growth factors, and their mimetics are addressed under current WADA rules. The World Anti-Doping Agency's prohibited list is updated annually, and substances may be added, reclassified, or removed. Athletes should verify current WADA classifications for any peptide-based therapy they are prescribed, as the sporting rules operate independently from FDA drug-shortage determinations.
Related Reading
- /compare/semaglutide-vs-tirzepatide/ — Clinical and regulatory comparison of the two leading incretin therapies
- /semaglutide/ — Latest on semaglutide supply, trials, and safety data
- /tirzepatide/ — Tirzepatide tracker: approvals, shortages, and compounding updates
- /regulatory/fda-warning-letters-tracker/ — Running log of FDA warning letters relevant to peptide and incretin drug products
- /regulatory/503a-vs-503b-compounding-explained/ — How federal compounding law applies to GLP-1 class drugs
